[Neurologic toxicity caused by zelitrex (valaciclovir) in 3 patients with renal failure. Is overdose associated with improvement of product bioavailability improvement?]
- PMID: 11270274
- DOI: 10.1016/s0248-8663(00)00332-5
[Neurologic toxicity caused by zelitrex (valaciclovir) in 3 patients with renal failure. Is overdose associated with improvement of product bioavailability improvement?]
Abstract
Introduction: We report three cases of neurotoxicity in patients with renal failure, treated with Zelitrex (valacyclovir).
Exegesis: The patients are two women and a man, aged 76 +/- 4.6 years, who presented acute mental confusion during a treatment with valacyclovir. In two cases, the patients previously had altered renal function and were under peritoneal dialysis. In the last case, the patient had simultaneous neurotoxicity and acute renal failure. After the discontinuation of the drug, the outcome was favourable in all cases.
Conclusion: Our cases focus attention on the possible neurotoxicity of valacyclovir, which is an amino acid ester prodrug of acyclovir, rapidly and almost completely hydrolysed to acyclovir prior to systemic exposure. The bioavailability of valacyclovir is 54% compared to approximately 20% for oral acyclovir and may account for unexpected overdoses, which may lead to serious neurological toxicity.
Similar articles
-
Pharmacokinetics and safety of multiple-dose valaciclovir in geriatric volunteers with and without concomitant diuretic therapy.Antimicrob Agents Chemother. 1996 Jan;40(1):80-5. doi: 10.1128/AAC.40.1.80. Antimicrob Agents Chemother. 1996. PMID: 8787884 Free PMC article. Clinical Trial.
-
Valacyclovir HCl (Valtrex): an acyclovir prodrug with improved pharmacokinetics and better efficacy for treatment of zoster.Adv Exp Med Biol. 1996;394:33-9. doi: 10.1007/978-1-4757-9209-6_4. Adv Exp Med Biol. 1996. PMID: 8815698 Review. No abstract available.
-
[Neurotoxicity of valacyclovir in a peritoneal dialysis patient].Hinyokika Kiyo. 2010 Nov;56(11):617-9. Hinyokika Kiyo. 2010. PMID: 21187705 Japanese.
-
Pharmacokinetics of the acyclovir pro-drug valaciclovir after escalating single- and multiple-dose administration to normal volunteers.Clin Pharmacol Ther. 1993 Dec;54(6):595-605. doi: 10.1038/clpt.1993.196. Clin Pharmacol Ther. 1993. PMID: 8275615 Clinical Trial.
-
Valaciclovir (BW256U87): the L-valyl ester of acyclovir.J Med Virol. 1993;Suppl 1:150-3. doi: 10.1002/jmv.1890410529. J Med Virol. 1993. PMID: 8245883 Review.
Cited by
-
MDR1 genotypes do not influence the absorption of a single oral dose of 600 mg valacyclovir in healthy Chinese Han ethnic males.Br J Clin Pharmacol. 2008 Aug;66(2):247-54. doi: 10.1111/j.1365-2125.2008.03189.x. Epub 2008 May 6. Br J Clin Pharmacol. 2008. PMID: 18460034 Free PMC article.
-
Use of Estimating Equations for Dosing Antimicrobials in Patients with Acute Kidney Injury Not Receiving Renal Replacement Therapy.J Clin Med. 2018 Aug 11;7(8):211. doi: 10.3390/jcm7080211. J Clin Med. 2018. PMID: 30103503 Free PMC article.
-
Acute renal failure and severe neurotoxicity following valacyclovir.Intensive Care Med. 2005 Nov;31(11):1593. doi: 10.1007/s00134-005-2808-9. Epub 2005 Sep 20. Intensive Care Med. 2005. PMID: 16172845 No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical